The 1,217-patient study showed that 71.5 percent of patients in the Rituxan group achieved complete or unconfirmed complete responses after two years vs. 52.5 percent in the observation group

The 702-patient study is testing the percent change in triglyceride level from baseline to week 12 as the primary endpoint

The 14-week, 65-patient study was not powered for efficacy, but results showed clinically relevant trends and, in two cases, statistical superiority of NP002 vs

The 118-patient study was designed to evaluate change in lung function following one week of dosing, as assessed by forced expiratory volume in one second, relative to baseline

The 24-patient study is designed to assess safety, tolerability and maximum tolerated dose

The 77-patient study, which randomized patients into six cohorts, showed a dose-dependent effect on blood pressure, with minimal or mild blood pressure reduction at the 1 .25 ng/kg/min and 2.5 ng/kg/min dose levels, and moderate blood pressure reduction at 3.75 ng/kg/min

The 24-to-30 patient study will evaluate safety, tolerability, pharmacokinetics and changes in MS clinical status

The 24-week, 311-patient study met its primary endpoint, with the addition of lixisenatide to basal insulin reducing A1C levels by 0.88 percent vs

Patients in the study taking the top dose of Qnexa achieved and maintained average weight loss through two years of 11.4 percent of their initial body weight, or 26 pounds

In this 80-patient study, the median overall survival time was 5.1 months for patients who received Zybrestat and chemotherapy when compared with a median survival time of 4.1 months for patients receiving chemotherapy alone (Hazard Ratio 0.71), which represents a 29 percent reduction in the risk of dying for patients receiving Zybrestat and chemotherapy

The 240-patient study will compare two doses of CF101 to placebo over a 24-week treatment period, with improvement of corneal fluorescein staining, tear production and dry eye symptom score as the main outcome assessments

The primary objectives of the 150-patient study are to estimate the progression-free survival hazard ratio of the combination treatment compared to paclitaxel alone and to determine the frequency and severity of adverse events

The 250-patient study is designed to test the drug head-to-head against methotrexate, with the primary efficacy analysis determined using the hybrid American College of Rheumatology score

The double-blind, active-controlled, investigator-initiated, 40-patient study was conducted in Germany

The 250-patient study will measure overall survival in prospectively defined hENT1-low patients as the primary endpoint and is designed to show statistically significant improvement

The company noted that although not part of the primary trial objectives, HCV-positive patients in the study were retested periodically to gauge the effect of CF102 on HCV infection in the liver cancer population

The 38-patient study also showed statistically significant reductions in the number of brain lesions, as measured on serial MRI scans from week eight to week 24, in the ofatumumab group vs

The four-patient study established that it was safe and feasible to transfect the lentiviral vector into human stem cells and for the RNA molecules to persist in the immune cells of patients undergoing autologous stem cell transplantation for AIDS-related lymphoma

The 55-patient study is evaluating objective response rate as the primary endpoint